MYC and diffuse large B-cell lymphoma: For this reason, combinations of targeted therapies, such as inhibitors that may target multiple anti-apoptotic BCL2 family members, combined with drugs that affect MYC, p53 pathway, immune escape genes and/or epigenetic regulators may lead to synergizing effects and could be beneficial for R/R DLBCL patients.